Bayard Powell to Tumor Suppressor Protein p53
This is a "connection" page, showing publications Bayard Powell has written about Tumor Suppressor Protein p53.
Connection Strength
0.252
-
Mims AS, Kohlschmidt J, Eisfeld AK, Mr?zek K, Blachly JS, Orwick S, Papaioannou D, Nicolet D, Sampath D, Stone RM, Powell BL, Kolitz JE, Byrd JC, Bloomfield CD. Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations. Leukemia. 2021 04; 35(4):1188-1192.
Score: 0.177
-
Roboz GJ, Mandrekar SJ, Desai P, Laumann K, Walker AR, Wang ES, Kolitz JE, Powell BL, Attar EC, Stock W, Bloomfield CD, Kohlschmidt J, Mrózek K, Hassane DC, Garraway L, Jané-Valbuena J, Baltay M, Tracy A, Marcucci G, Stone RM, Larson RA. Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Adv. 2018 12 26; 2(24):3608-3617.
Score: 0.040
-
Kytola V, Topaloglu U, Miller LD, Bitting RL, Goodman MM, D Agostino RB, Desnoyers RJ, Albright C, Yacoub G, Qasem SA, DeYoung B, Thorsson V, Shmulevich I, Yang M, Shcherban A, Pagni M, Liu L, Nykter M, Chen K, Hawkins GA, Grant SC, Petty WJ, Alistar AT, Levine EA, Staren ED, Langefeld CD, Miller V, Singal G, Petro RM, Robinson M, Blackstock W, Powell BL, Wagner LI, Foley KL, Abraham E, Pasche B, Zhang W. Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center. Theranostics. 2017; 7(11):2914-2923.
Score: 0.036